Back

Alteogen signs Novartis deal worth up to $3.223 billion for ALT-B4

Verifying
  • Alteogen signed Novartis an exclusive option and license agreement for ALT-B4 formulations.
  • The agreement could pay Alteogen up to $3.223 billion before separately calculated sales royalties.
  • Alteogen’s 2025 technology-transfer agreements total ₩6.2259 trillion, including three earlier deals.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.